Oncolysin B

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOncolysin B

Drug Alias NameAnti-CD19-bRB4 blocked ricinAnti-B4-bR

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsProtein biosynthesis inhibitorsImmunosuppressants

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinLymphomaLeukemia

ATC CodeN/A